- Home
- TEN vs PRAX Comparison
TEN vs PRAX Comparison
Compare TEN & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEN
- PRAX
- Stock Information
- Founded
- TEN 1993
- PRAX 2015
- Country
- TEN Greece
- PRAX United States
- Employees
- TEN N/A
- PRAX N/A
- Industry
- TEN
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- TEN
- PRAX Health Care
- Exchange
- TEN NYSE
- PRAX Nasdaq
- Market Cap
- TEN 595.6M
- PRAX 599.7M
- IPO Year
- TEN N/A
- PRAX 2020
- Fundamental
- Price
- TEN $20.74
- PRAX $50.36
- Analyst Decision
- TEN Buy
- PRAX Strong Buy
- Analyst Count
- TEN 2
- PRAX 10
- Target Price
- TEN $30.50
- PRAX $101.00
- AVG Volume (30 Days)
- TEN 463.7K
- PRAX 305.1K
- Earning Date
- TEN 06-17-2025
- PRAX 08-12-2025
- Dividend Yield
- TEN 7.35%
- PRAX N/A
- EPS Growth
- TEN N/A
- PRAX N/A
- EPS
- TEN 4.46
- PRAX N/A
- Revenue
- TEN $799,523,000.00
- PRAX $8,122,000.00
- Revenue This Year
- TEN N/A
- PRAX N/A
- Revenue Next Year
- TEN $9.46
- PRAX $6,358.50
- P/E Ratio
- TEN $4.57
- PRAX N/A
- Revenue Growth
- TEN N/A
- PRAX 270.02
- 52 Week Low
- TEN $13.40
- PRAX $26.70
- 52 Week High
- TEN $28.19
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- TEN 60.41
- PRAX 71.71
- Support Level
- TEN $20.08
- PRAX $45.70
- Resistance Level
- TEN $20.84
- PRAX $53.35
- Average True Range (ATR)
- TEN 0.65
- PRAX 2.51
- MACD
- TEN -0.01
- PRAX 0.55
- Stochastic Oscillator
- TEN 72.69
- PRAX 76.02
About TEN TSAKOS ENERGY NAVIGATION
Tsakos Energy Navigation Ltd is a seaborne transportation service provider for crude oil and petroleum products. The company's carriers cater to national and international independent oil companies and refiners. It generates revenue through charter contracts with its clients, which include time, bareboat, and voyage charters, contracts of affreightment, and pool arrangements.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.